RU2549551C2 - Производные диазагомоадамантана и способы их применения - Google Patents

Производные диазагомоадамантана и способы их применения Download PDF

Info

Publication number
RU2549551C2
RU2549551C2 RU2012101784/04A RU2012101784A RU2549551C2 RU 2549551 C2 RU2549551 C2 RU 2549551C2 RU 2012101784/04 A RU2012101784/04 A RU 2012101784/04A RU 2012101784 A RU2012101784 A RU 2012101784A RU 2549551 C2 RU2549551 C2 RU 2549551C2
Authority
RU
Russia
Prior art keywords
diazatricyclo
undecane
pyridin
pain
alkyl
Prior art date
Application number
RU2012101784/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2012101784A (ru
Inventor
Майкл Р. ШРИМПФ
Кевин Б. СИППИ
Original Assignee
Эббви Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43354879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2549551(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эббви Инк. filed Critical Эббви Инк.
Publication of RU2012101784A publication Critical patent/RU2012101784A/ru
Application granted granted Critical
Publication of RU2549551C2 publication Critical patent/RU2549551C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
RU2012101784/04A 2009-06-19 2010-06-18 Производные диазагомоадамантана и способы их применения RU2549551C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21847909P 2009-06-19 2009-06-19
US61/218,479 2009-06-19
PCT/CN2010/000889 WO2010145208A1 (en) 2009-06-19 2010-06-18 Diazahomoadamantane derivatives and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2015110025/04A Division RU2015110025A (ru) 2009-06-19 2010-06-18 Производные диазагомоадамантана и способы их применения

Publications (2)

Publication Number Publication Date
RU2012101784A RU2012101784A (ru) 2013-07-27
RU2549551C2 true RU2549551C2 (ru) 2015-04-27

Family

ID=43354879

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2012101784/04A RU2549551C2 (ru) 2009-06-19 2010-06-18 Производные диазагомоадамантана и способы их применения
RU2015110025/04A RU2015110025A (ru) 2009-06-19 2010-06-18 Производные диазагомоадамантана и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015110025/04A RU2015110025A (ru) 2009-06-19 2010-06-18 Производные диазагомоадамантана и способы их применения

Country Status (15)

Country Link
US (1) US8846661B2 (enExample)
EP (1) EP2443122B1 (enExample)
JP (1) JP2012530084A (enExample)
KR (1) KR20120044978A (enExample)
CN (1) CN102459268A (enExample)
AU (1) AU2010262643B2 (enExample)
BR (1) BRPI1015043A2 (enExample)
CA (1) CA2765466A1 (enExample)
IL (2) IL216883A (enExample)
MX (1) MX2011014019A (enExample)
NZ (1) NZ597511A (enExample)
PE (1) PE20121066A1 (enExample)
RU (2) RU2549551C2 (enExample)
SG (1) SG176921A1 (enExample)
WO (1) WO2010145208A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2809028C (en) * 2010-08-20 2019-04-09 Research Triangle Institute Nicotinic receptor compounds
CN103087001A (zh) * 2011-11-03 2013-05-08 南京大学 香草酸的1,3,4-噁二唑衍生物及其制法和用途
WO2014165090A1 (en) * 2013-03-13 2014-10-09 The Broad Institute, Inc. Compounds for the treatment of tuberculosis
RU2552649C1 (ru) * 2013-12-13 2015-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет тонких химических технологий имени М.В. Ломоносова" (МИТХТ им. М.В. Ломоносова) Душистые 5-бензил-1,3-диазаадамантан-6-оны
WO2015103005A1 (en) * 2014-01-03 2015-07-09 Research Institute At Nationwide Children's Hospital Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers
WO2016100184A1 (en) 2014-12-16 2016-06-23 Forum Pharmaceuticals, Inc. Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
JP2018516973A (ja) 2015-06-10 2018-06-28 フォーラム・ファーマシューティカルズ・インコーポレイテッドForum Pharmaceuticals Inc. α7−ニコチン性アセチルコリン受容体のアゴニストとしてのアミノベンゾイソオキサゾール化合物
EP3334740A4 (en) 2015-08-12 2019-02-06 Axovant Sciences GmbH GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS
CN108697709A (zh) * 2015-12-10 2018-10-23 Ptc医疗公司 用于治疗亨廷顿病的方法
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
AU2019219678A1 (en) * 2018-02-08 2020-08-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2162469C2 (ru) * 1995-11-02 2001-01-27 Ньюросерч А/С Конденсированные тропановые производные в качестве ингибиторов обратного захвата нейромедиаторов
RU2219179C2 (ru) * 1998-08-18 2003-12-20 ЮСиБи С.А. Азациклические соединения, фармацевтические композиции
WO2008118742A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Azaadamantane ester and carbamate derivatives and methods of use thereof
WO2008118743A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof
WO2008118747A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Amimomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557865A (en) * 1984-05-07 1985-12-10 Pennwalt Corporation Substituted 4-azatricyclo[4.3.1.13,8 ]undecane compounds
CA2348879A1 (en) * 1998-11-02 2000-05-11 Welfide Corporation Pyrrolidine compound and pharmaceutical use thereof
CA2450167A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7482338B2 (en) * 2003-09-26 2009-01-27 Astrazeneca Ab Non-amide nonanes
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200840569A (en) * 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
CA2771885C (en) 2009-09-14 2014-04-08 Suven Life Sciences Limited 1,2-dihydro-2-oxoquinoline compounds as 5-ht4receptor ligands

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2162469C2 (ru) * 1995-11-02 2001-01-27 Ньюросерч А/С Конденсированные тропановые производные в качестве ингибиторов обратного захвата нейромедиаторов
RU2219179C2 (ru) * 1998-08-18 2003-12-20 ЮСиБи С.А. Азациклические соединения, фармацевтические композиции
WO2008118742A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Azaadamantane ester and carbamate derivatives and methods of use thereof
WO2008118743A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof
WO2008118747A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Amimomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs)

Also Published As

Publication number Publication date
KR20120044978A (ko) 2012-05-08
NZ597511A (en) 2014-01-31
IL216883A0 (en) 2012-02-29
AU2010262643A1 (en) 2012-02-02
CA2765466A1 (en) 2010-12-23
WO2010145208A1 (en) 2010-12-23
EP2443122B1 (en) 2014-03-05
RU2012101784A (ru) 2013-07-27
CN102459268A (zh) 2012-05-16
US20100324027A1 (en) 2010-12-23
MX2011014019A (es) 2012-02-22
US8846661B2 (en) 2014-09-30
EP2443122A1 (en) 2012-04-25
BRPI1015043A2 (pt) 2019-07-09
SG176921A1 (en) 2012-01-30
IL236830A0 (en) 2015-03-31
AU2010262643B2 (en) 2015-02-19
EP2443122A4 (en) 2012-12-19
RU2015110025A (ru) 2015-08-20
IL216883A (en) 2015-02-26
JP2012530084A (ja) 2012-11-29
PE20121066A1 (es) 2012-09-13

Similar Documents

Publication Publication Date Title
RU2549551C2 (ru) Производные диазагомоадамантана и способы их применения
US8163916B2 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
JP5394939B2 (ja) 4−置換アザアダマンタン誘導体およびそれの使用方法
JP5364878B2 (ja) アザアダマンタンのアセトアミドおよびカルボキサミド誘導体ならびにそれらの使用方法
JP5394940B2 (ja) アミノメチルアザアダマンタン誘導体およびα7−神経ニコチン性アセチルコリン受容体(NNR類)の選択的調節剤としてのそれの使用
AU2015202090A1 (en) Diazahomoadamantane derivatives and methods of use thereof
HK1131609B (en) Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof
HK1135972B (en) 4-substituted azaadamantane derivatives and methods of use thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160619